Ellsworth Advisors LLC Increases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Ellsworth Advisors LLC grew its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,612 shares of the life sciences company’s stock after buying an additional 4,112 shares during the quarter. Integra LifeSciences accounts for approximately 1.5% of Ellsworth Advisors LLC’s holdings, making the stock its 18th biggest holding. Ellsworth Advisors LLC’s holdings in Integra LifeSciences were worth $4,643,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IART. Itau Unibanco Holding S.A. raised its position in shares of Integra LifeSciences by 469.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after buying an additional 615 shares in the last quarter. Gladius Capital Management LP purchased a new stake in shares of Integra LifeSciences during the 3rd quarter valued at about $47,000. Covestor Ltd grew its holdings in Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 921 shares during the last quarter. Coppell Advisory Solutions LLC bought a new position in Integra LifeSciences during the 2nd quarter valued at about $84,000. Finally, Captrust Financial Advisors grew its holdings in Integra LifeSciences by 95.0% during the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after purchasing an additional 976 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Up 1.8 %

Shares of IART traded up $0.62 during mid-day trading on Friday, hitting $35.45. The company’s stock had a trading volume of 823,648 shares, compared to its average volume of 854,022. The company’s 50-day moving average is $39.49 and its 200-day moving average is $39.70. Integra LifeSciences Holdings Co. has a 52-week low of $33.24 and a 52-week high of $59.33. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 42.71, a PEG ratio of 1.05 and a beta of 1.13. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same period in the previous year, the company posted $0.94 EPS. Integra LifeSciences’s revenue for the quarter was down .3% on a year-over-year basis. On average, equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IART shares. JMP Securities cut their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Wells Fargo & Company upgraded shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $40.00 to $49.00 in a report on Tuesday, December 5th. Truist Financial cut their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Finally, StockNews.com upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $45.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.